Meeting space has been assigned to provide a satellite symposium supported by GSK during the Oncology Nursing Society’s (ONS) 50th Annual Congress, April 9-13, 2025 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

Program Schedule — Mountain Time
5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting

Biology of Endometrial Cancer (EC); Rationale for the Use of Immune Checkpoint Inhibitors

• Historic role of and outcomes achieved with chemotherapy as first-line treatment for patients with primary advanced or recurrent EC
• Similarities and differences among the anti-PD-1/PD-L1 antibodies currently available for EC — dostarlimab, pembrolizumab and durvalumab
• Biologic rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with EC
• Frequency of potential biomarkers of response to immune checkpoint inhibitors for EC, such as microsatellite instability (MSI)/mismatch repair (MMR) deficiency and POLE mutations; optimal approach to biomarker assessment for patients with newly diagnosed disease

First-Line Therapy for Advanced or Recurrent EC

• Key efficacy findings with dostarlimab, pembrolizumab and durvalumab, respectively, in combination with chemotherapy as first-line treatment for advanced or recurrent EC
• Correlation, if any, between MSI/MMR status and outcomes with the addition of anti-PD-1/PD-L1 antibodies to chemotherapy
• FDA approval of dostarlimab and of pembrolizumab in combination with chemotherapy for patients with advanced or recurrent EC regardless of MSI/MMR status and of durvalumab in combination with chemotherapy for those with MMR-deficient disease
• Optimal incorporation of anti-PD-1/PD-L1 antibodies into up-front therapy for patients with advanced or recurrent EC

Potential Benefits of PARP Inhibition Combined with Immunotherapy for Advanced EC

• Mechanism of antitumor activity of PARP inhibitors and biological rationale for their investigation in EC; potential therapeutic synergy between PARP inhibitors and immune checkpoint inhibitors
• Published efficacy and safety results with durvalumab and chemotherapy followed by maintenance durvalumab and olaparib for patients with newly diagnosed advanced or recurrent EC
• Benefits observed with first-line dostarlimab and carboplatin/paclitaxel followed by maintenance dostarlimab/niraparib compared to carboplatin/paclitaxel alone for advanced or recurrent EC
• Potential role of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors in the care of patients with EC

Tolerability and Other Practical Considerations with the Use of Anti-PD-1/PD-L1 Antibodies for Previously Untreated Advanced EC

• Pathophysiology, incidence and spectrum of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies for advanced EC
• Recommended monitoring and management of immune-related and other AEs with immune checkpoint inhibitors
• Strategies to discern whether toxicities stem from anti-PD-1/PD-L1 antibodies or their therapeutic combination partners, such as chemotherapy or PARP inhibitors
• Role of rechallenge when immune checkpoint inhibitor therapy has been held because of immune-mediated toxicity
• Relative and absolute contraindications to anti-PD-1/PD-L1 antibody therapy; role, if any, of this therapy for patients with preexisting autoimmune conditions or a history of solid organ transplant

Potential Role of Selinexor in the Management of Previously Untreated EC

• Clinical significance of TP53 mutation status in patients with advanced EC; appropriate means of testing
• Mechanism of action of selinexor and biological rationale for its evaluation in EC, particularly TP53 wild-type disease
• Available efficacy and safety findings with selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent EC; outcomes achieved in patients with TP53 wild-type disease
• Ongoing Phase III evaluation of maintenance selinexor after first-line chemotherapy for TP53 wild-type advanced EC

Tolerability Considerations with Selinexor

• Spectrum, frequency and severity of gastrointestinal (GI) toxicities associated with selinexor
• Strategies to prevent and manage GI AEs with selinexor; recommended preemptive medication for nausea and vomiting
• Appropriate monitoring for and management of other selinexor-related toxicities, such as neutropenia, thrombocytopenia and hyponatremia
• Starting dose and dose-modification strategies with selinexor for EC

Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC

• Biological rationale for combining immune checkpoint inhibitors with agents targeting the VEGF pathway in EC
• Major findings, including overall survival data, supporting the use of lenvatinib in combination with pembrolizumab for patients with MMR-proficient advanced EC and disease progression after prior systemic therapy
• Optimal integration of lenvatinib/pembrolizumab into current EC management algorithms
• Utility of lenvatinib/pembrolizumab for patients who have experienced disease progression on up-front chemoimmunotherapy

Toxicities with Lenvatinib/Pembrolizumab

• Incidence, severity, timing and management of AEs observed in patients with EC receiving lenvatinib/pembrolizumab, such as hypertension, GI symptoms, weight loss and hand-foot syndrome
• Approaches to encourage adequate nutrition for patients receiving the combination of lenvatinib and pembrolizumab
• Initial dosing and dose-modification strategies with lenvatinib/pembrolizumab for EC; available data exploring the impact of lenvatinib dose reductions on antitumor activity
• Strategies to determine the cause of toxicities that might stem from either lenvatinib or pembrolizumab

Incidence and Management of HER2-Positive EC

• Frequency of HER2 expression in advanced EC; optimal timing of and approach to testing
• Current clinical role of trastuzumab as a component of therapy for HER2-positive uterine serous carcinoma and carcinosarcoma
• Structural components and mechanism of antitumor activity of trastuzumab deruxtecan (T-DXd); efficacy and safety outcomes observed with T-DXd among patients with advanced EC
• FDA approval of T-DXd for pretreated HER2-positive solid tumors; implications for EC management
• Spectrum and incidence of common (eg, GI toxicities, myelosuppression) and more serious (eg, interstitial lung disease, cardiac toxicities) treatment-emergent AEs with T-DXd; recommendations for monitoring and management

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of endometrial cancer.

There is no registration fee for this event. For the in-person symposium in Denver, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2025 ONS Congress.

To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.